Daunorubicin Citrate
FDA-approved product (injectable, liposomal, injection), marketed as Daunoxome, Cerubidine, Daunorubicin Hydrochloride.
- Registered studies
- 50+
- Lab records
- 2
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Acute myeloid leukemia
- Lymphoid leukemia
- Neoplasm
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Anthracyclines and related substances
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA52.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- E. coli30.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae28.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis53.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
- MRSA: measured active in 2 of 2 lab records
Show the 2 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Daunorubicin Citrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT00915252 · start 2009-07
Registered record
- Registry ID
- NCT00915252
- Conditions
- Acute Myeloid Leukemia
- Interventions
- azacitidine; standard chemotherapy (7+3 scheme): Daunorubicin, Cytarabine
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2009-07
- Completion
- 2012-12
- Enrolment
- 214
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Myeloid LeukemiaInterventionazacitidine; standard chemotherapy (7+3 scheme): Daunorubicin, CytarabinePhasePhase 2Registry statusCompletedExploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer
NCT00656669 · start 2008-04
Registered record
- Registry ID
- NCT00656669
- Conditions
- Breast Cancer
- Interventions
- sunitinib alone; sunitinib plus paclitaxel; doxorubicin and cyclophosphamide
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2008-04
- Completion
- 2010-09
- Enrolment
- 23
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast CancerInterventionsunitinib alone; sunitinib plus paclitaxel; doxorubicin and cyclophosphamidePhaseNot applicableRegistry statusCompletedTipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
NCT00470301 · start 2007-04
Registered record
- Registry ID
- NCT00470301
- Conditions
- Breast Cancer; Male Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
- Interventions
- tipifarnib; paclitaxel; doxorubicin; cyclophosphamide
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Completed
- Start
- 2007-04
- Completion
- 2013-09
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast Cancer; Male Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer +2 moreInterventiontipifarnib; paclitaxel; doxorubicin; cyclophosphamidePhasePhase 1 / Phase 2Registry statusCompletedChemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery
NCT00408408 · start 2006-11
Registered record
- Registry ID
- NCT00408408
- Conditions
- Breast Cancer
- Interventions
- bevacizumab; capecitabine; cyclophosphamide; docetaxel; doxorubicin hydrochloride (Adriamycin); gemcitabine hydrochloride
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Unknown
- Start
- 2006-11
- Completion
- 2018-03
- Enrolment
- 1,206
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast CancerInterventionbevacizumab; capecitabine; cyclophosphamide; docetaxel +2 morePhasePhase 3Registry statusUnknownTreating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease
NCT00107198 · start 2006-03-10
Registered record
- Registry ID
- NCT00107198
- Conditions
- Ann Arbor Stage I Childhood Hodgkin Lymphoma; Ann Arbor Stage II Childhood Hodgkin Lymphoma; Childhood Nodular Lymphocyte Predominant B-Cell Lymphoma
- Interventions
- Conventional Surgery; Cyclophosphamide; Doxorubicin Hydrochloride; Prednisone; Radiation Therapy; Vincristine Sulfate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2006-03-10
- Completion
- 2026-03-31
- Enrolment
- 188
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnn Arbor Stage I Childhood Hodgkin Lymphoma; Ann Arbor Stage II Childhood Hodgkin Lymphoma; Childhood Nodular Lymphocyte Predominant B-Cell LymphomaInterventionConventional Surgery; Cyclophosphamide; Doxorubicin Hydrochloride; Prednisone +2 morePhasePhase 2Registry statusCompletedNeoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients
NCT00270894 · start 2005-11
Registered record
- Registry ID
- NCT00270894
- Conditions
- Breast Neoplasm
- Interventions
- epirubicin; cyclophosphamide; docetaxel; trastuzumab
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2005-11
- Completion
- 2011-08
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast NeoplasmInterventionepirubicin; cyclophosphamide; docetaxel; trastuzumabPhasePhase 2Registry statusCompletedImatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00618501 · start 2005-10
Registered record
- Registry ID
- NCT00618501
- Conditions
- Leukemia
- Interventions
- cytarabine; daunorubicin hydrochloride; etoposide; imatinib mesylate; leucovorin calcium; methotrexate; prednisolone; therapeutic hydrocortisone; vincristine sulfate; allogeneic hematopoietic stem cell transplantation
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2005-10
- Completion
- 2009-01
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLeukemiaInterventioncytarabine; daunorubicin hydrochloride; etoposide; imatinib mesylate +6 morePhasePhase 2Registry statusCompletedChemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia
NCT00458848 · start 2004-10
Registered record
- Registry ID
- NCT00458848
- Conditions
- Leukemia
- Interventions
- asparaginase; daunorubicin hydrochloride; etoposide; idarubicin; imatinib mesylate; mercaptopurine; methotrexate; methylprednisolone; mitoxantrone hydrochloride; prednisone; vincristine sulfate; allogeneic hematopoietic stem cell transplantation; autologous hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; radiation therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2004-10
- Completion
- 2014-03
- Enrolment
- 470
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLeukemiaInterventionasparaginase; daunorubicin hydrochloride; etoposide; idarubicin +11 morePhasePhase 2Registry statusCompletedCombination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery
NCT00194779 · start 2003-10
Registered record
- Registry ID
- NCT00194779
- Conditions
- Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer
- Interventions
- doxorubicin hydrochloride; cyclophosphamide; paclitaxel; filgrastim; capecitabine; methotrexate; vinorelbine tartrate; needle biopsy; therapeutic conventional surgery; immunohistochemistry staining method; trastuzumab; tamoxifen citrate; letrozole; laboratory biomarker analysis
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2003-10
- Completion
- 2011-06
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEstrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Progesterone Receptor-negative Breast Cancer +5 moreInterventiondoxorubicin hydrochloride; cyclophosphamide; paclitaxel; filgrastim +10 morePhasePhase 2Registry statusCompletedEpirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
NCT00062296 · start 2003-03
Registered record
- Registry ID
- NCT00062296
- Conditions
- Leukemia; Lymphoma
- Interventions
- rituximab; epirubicin hydrochloride
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2003-03
- Completion
- 2005-08
- Enrolment
- 5
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLeukemia; LymphomaInterventionrituximab; epirubicin hydrochloridePhasePhase 2Registry statusCompletedStudy of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)
NCT00130195 · start 2002-09
Registered record
- Registry ID
- NCT00130195
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- imatinib; cyclophosphamide; daunorubicin; vincristine; prednisolone; methotrexate; cytarabine; dexamethasone
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2002-09
- Completion
- 2008-05
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Lymphoblastic LeukemiaInterventionimatinib; cyclophosphamide; daunorubicin; vincristine +4 morePhasePhase 2Registry statusCompletedRituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma
NCT00669877 · start 2002-08
Registered record
- Registry ID
- NCT00669877
- Conditions
- Burkitt's Lymphoma; Burkitt'S-like Lymphoma
- Interventions
- Rituximab; Cyclophosphamide; Doxorubicin; Vincristine; Dexamethasone; G-CSF; Cytarabine; Methotrexate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2002-08
- Completion
- 2015-10
- Enrolment
- 56
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBurkitt's Lymphoma; Burkitt'S-like LymphomaInterventionRituximab; Cyclophosphamide; Doxorubicin; Vincristine +4 morePhasePhase 2Registry statusCompletedTITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma
NCT00002757 · start 2001-06
Registered record
- Registry ID
- NCT00002757
- Conditions
- Leukemia; Lymphoma
- Interventions
- filgrastim; cyclophosphamide; cytarabine; doxorubicin hydrochloride; etoposide; methotrexate; prednisolone; prednisone; therapeutic hydrocortisone; vincristine sulfate
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2001-06
- Completion
- 2009-10
- Enrolment
- 1,148
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLeukemia; LymphomaInterventionfilgrastim; cyclophosphamide; cytarabine; doxorubicin hydrochloride +6 morePhasePhase 3Registry statusCompletedCombination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin
NCT00022178 · start 1998-12
Registered record
- Registry ID
- NCT00022178
- Conditions
- Carcinoma of Unknown Primary
- Interventions
- cisplatin; cyclophosphamide; doxorubicin hydrochloride; epirubicin hydrochloride; fluorouracil; vincristine sulfate
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Unknown
- Start
- 1998-12
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCarcinoma of Unknown PrimaryInterventioncisplatin; cyclophosphamide; doxorubicin hydrochloride; epirubicin hydrochloride +2 morePhasePhase 3Registry statusUnknownTreatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years
NCT00464217 · start 1998-10
Registered record
- Registry ID
- NCT00464217
- Conditions
- Acute Myeloblastic Leukaemia
- Interventions
- ARA-C; Idarubicin; Leucomax
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 1998-10
- Completion
- 2008-12
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Myeloblastic LeukaemiaInterventionARA-C; Idarubicin; LeucomaxPhasePhase 4Registry statusCompleted